Document is current

Article History

Received: 27 December 2025

Accepted: 11 February 2026

First Online: 21 February 2026

Declarations

:

: M. Stelljes: Consulting/Advisory Role: Pfizer, MSD, Bristol-Myers Squibb, Incyte, Takeda, Astellas, Autolus, Sanofi and Amgen; speaker honoraria: Medac, MSD, Astellas, Jazz Pharmaceuticals, Amgen, Novartis, Gilead, Celgene, BMS, AbbVie, and Incyte; Reseach funding: Pfizer; Conferences/Travel support: Medac, Sanofi and Pfizer. R. Zeiser: Consulting/Advisory Role: Novartis, Sanofi, Incyte, medac and Therakos. F. Ayuk: Honoraria: AbbVie, BMS, Kite/Gilead, Janssen, Therakos, Miltenyi Biomedicine, Novartis, Takeda, Medac, Neovii; Research funding: Therakos, Neovii G. Lenz: received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. G.L. received honoraria not related to this study from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi. P. Dreger: consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speaker honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. P Dreger is current chairman of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT). A. Sureda: Consultancy: Takeda, Abbvie, GenMab, MSD, BMS Celgene, Gilead Kite, Allogene, Autolus, Roche, Novartis; Speakers Bureau: Takeda; Travel: Janssen, Takeda, Gilead Kite, Abbvie. Speaker honoraria: Takeda, BMS Celgene, GenMab, Abbvie, Janssen, Gilead Kite, Vertex, Sanofi; Research support: Takeda, BMS Celgene; A. Sureda is the current President of the EBMT. G. Damaj: Honoraria: Takeda, Amgen. Travel support: Takeda. Research Support: Takeda, Ideogen. A. Bazarbachi: Speaker bureau or advisory board: Novartis, Roche, Sanofi, Jazz, Adienne, Astellas, Takeda, Hikma, Celgene, Jansen, MSD, Abbvie, Pfizer and Amgen. Research support: Novartis, Roche, Takeda, Jansen, Astellas, Celgene, Pfizer and Amgen. N. Schmitz: Honoraria: Gilead Kite, Roche. Travel support: Beigene, Glilead Kite, Roche Research support: Astra Zeneca, Janssen.